---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-152368"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2021-12-22T23:59:59+00:00"
generated_at: "2026-06-27T23:00:46.951773+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immuneering acquires BioArkive for $8.75M in stock; delays IMM-1-104 IND to Q3 2022

## Summary
- Acquired BioArkive for $8.75M in stock (379,635 shares); BioArkive CRO to be fully integrated into Immuneering.
- Assumed BioArkive's San Diego lease: 38,613 sq ft, monthly base rent ~$56K, term through April 2032.
- IMM-1-104 IND submission delayed to Q3 2022; first patient enrollment now Q4 2022 due to supply chain constraints.
- 28 BioArkive employees become Immuneering employees; Brett Hall (Immuneering CSO) held majority of BioArkive shares.

## SEC filing metadata
- accession: 0001104659-21-152368
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2021-12-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000110465921152368/0001104659-21-152368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000110465921152368/tm2136034d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-152368
- JSON: https://secwatch.observer/filing/0001104659-21-152368.json
- Plain text: https://secwatch.observer/filing/0001104659-21-152368.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.